Identification of cytochromes P450 involved in human liver microsomal metabolism of ecabapide, a prokinetic agent

References

• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• DISRELATH M., REILLY, P. E. B., MARTIN, M. V., DAVIS, G. G., WILKINSON, G. R. and GUENGERICH F. P., 1985, Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin 0-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 260, 9057–9067.
   PubMedGoogle Scholar
• FUJIMAKI, Y., HOSOKAMI, T. and ONO, K., 1995, Identification of urinary metabolites of ecabapide in rat. Xenobiotica, 25, 501–510.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochronw P450: Structure, Mechanism, and Biochemistry (New York: Plenum), pp. 473–535.
   Google Scholar
• GONZALEZ, F. J., 1997, Overview of experimental approaches for study of drug metabolism and drug—drug interactions. In A. P. Li (ed.), Advance in Pharmacology, Drug-drug Interactions: Scientific and Regulatory Perspectives (San Diego: Academic Press), pp. 255-277.
   Google Scholar
• GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLFF, T. and WAXMAN, D. J., 1986b, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 261, 5051–5060.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., MULLER -ENOCH, D. and BLAIR, I. A., 1986a, Oxidation of quinidine by human liver microsomal P450. Molecular Pharmacology, 30, 287–295.
   Google Scholar
• HATANAKA, S., HOSOKAW, T., KAWARABAYASHI, K., IsBu, M., TSUBOKURA, K. and FURUHAMA, K., 1995a, Pharmacological characteristics of DQ-2511 as a prokinetic agent. Archives Internatianales Pharmacodynamk Therapie, 330, 332–344.
   PubMedGoogle Scholar
• HATANAKA, S., KAWARABAYASHI, K., IsERI, M., TSUBOKURA, K. and FURUHAMA, K., 1995b, Enhancing effect of DQ-2511 on gastric emptying of spontaneously hypertensive rats. Life Science, 56, PL377–382.
   PubMedGoogle Scholar
• ITo, K., IWATSUBO, T., KANAMITSU, S., UEDA, K., Suzum, H. and SUGIYAMA, Y., 1998, Prediction of pharmacokinetic alternations caused by drug—drug interactions: metabolic interaction in the liver. Pharmacological Reviews, 50, 387–411.
   PubMed Web of Science ®Google Scholar
• KAWARABAYASHI, K., HATANAKA, S., IsBu, M., TSUBOKURA, K. and FURUHAMA, K., 1995, Potential of DQ-2511 as a gastrokinetic agent: Improving action on delayed gastric emptying. Japan Journal of Pharmacology, 67, 197P.
   Google Scholar
• KLEINBLOESEM C. H., VAN BRUMMELEN, P. and BREMER, D. D., 1987, Nifedipine, relationship between pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetks, 12, 12–29.
   Google Scholar
• MAURICE, M., PICHARD, L., DAUJAT, M., FABRE, I., JoyEux, H., DOMERGUE, J. and MAUREL, P., 1992, Effects of imidazole derivatives on cytochromes P-450 from human hepatocytes in primary culture. FASEB Journal, 6, 752–758.
   PubMed Web of Science ®Google Scholar
• NAKAOKA, M., TSUMURA M., ICHIKAWA, E., Suzum, W., HAKUSUI, H. and NAKAZAWA, T., 1996, Identification of major biliary and urinary metabolites of ecabapide in rats. Xenobiotica, 26, 983–994.
   Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1994, Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   Google Scholar
• ONO, C., FUJEVIAKI, Y. and TSUMURA, M., 1995, Metabolism of ecabapide, a novel prokinetic agent, by rat liver microsomes. In Proceedings of the 116th Annual Meeting of the Pharmaceutical Society of Japan, 27N2 15–3.
   Google Scholar
• SUNDHEIMER, D. W., CAVENESS, M. B. and GOLDSTEIN, J. A., 1983, Differential metabolism of acetanilide versus ethoxycoumarin and benzo(a)pyrene by two 3-methylcholanthrene-inducible forms of rat liver cytochrome P-450. Archives of Biochemistry and Biophysics, 226, 548–557.
   PubMed Web of Science ®Google Scholar
• TSUMURA M., TSUTSUMI, S., KARASAWA, Y. and Esumi, Y., 1996, Metabolic fate of ecabapide in rats. In Proceedings of the 116th Annual Meeting of the Pharmaceutical Society of Japan, 29M 11–2.
   Google Scholar
• WATKINS, P. B., WRIGHTON, S. A., MAUREL, P., SCHUETZ, E. G., MENDEZ -PICON, G., PARKER, G. A. and GUZELIAN, P. S., 1985, Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy Sciences, USA, 82, 6310–6314.
   Google Scholar
• WAXMAN, D. J., ATTISANO, C., GUENGERICH, F. P. and LAPENSON, D. P., 1988, Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6/3-hydroxylase cytochrome P450 enzyme. Archives of Biochemistry and Biophysics, 263, 424–436.
   PubMed Web of Science ®Google Scholar
• WILKINSON, G. R., 1996, Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. Journal of Pharmacokinetics and Biopharmaceutics, 24, 475–490.
   PubMedGoogle Scholar
• WIUGHTON, S. A., RING, B. J., WATKINS, P. B. and VANDEN BRANDEN, M., 1989, Identification of a polymorphically expressed member of the human cytochrome P-450III family. Molecular Pharmacology, 36, 97–105.
   PubMedGoogle Scholar
• WIUGHTON, S. A. and STEVENS, J. C., 1992, The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology, 22, 1–21.
   PubMedGoogle Scholar
• WIUGHTON, S. A., VANDEN BRANDEN, M. and RING, B. J., 1996, The human drug metabolizing cytochromes P450. Journal of Pharmacokinetics and Biopharmaceutics, 24, 461–473.
   PubMedGoogle Scholar